thedeepdive2d
Cassava Sciences Stock Plummets Amid Trial Failure and Shkreli’s Takedown
Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...
FierceBiotech3d
Cassava flunks phase 3 Alzheimer's test, triggering early end of 2nd trial and stock crash
Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...
Cassava Sciences: Probably The End Of The Saga
Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...
ATTENTION SAVA SHAREHOLDERS: Investors who Lost Money on Cassava Sciences, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
bovnews1d
Cassava Sciences Inc (SAVA) Stock: Beyond the Surface of Its Performance?
On Tuesday, Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $3.83 which represents a decrease of $-0.47 or -10.93% from the prior close of $4.3. The stock opened at $4.32 and ...
LEADERSHIP Newspaper1d
Senate Pushes For Cassava Inclusion In Flour Production
The Nigerian Senate has advanced efforts to mandate the inclusion of cassava in flour production and its derivatives.
Cassava Sciences downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino downgraded Cassava Sciences (SAVA) to Neutral from Buy without a price target after the company ...
pharmaphorum2d
End looms for Cassava's simufilam in Alzheimer's disease
Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...